14.2 Refractory Septic Shock & Adjunctive Therapies

Septic shock unresponsive to initial fluid resuscitation and moderate doses of first-line vasopressors represents a high-mortality clinical emergency. In this phase of critical illness, pathological vasodilation (vasoplegia), adrenergic receptor downregulation, intrinsic neurohormonal exhaustion, and myocardial depression conspire to produce refractory circulatory collapse. Managing this complex state requires a structured, evidence-based algorithm for vasoactive escalation alongside targeted adjunctive therapies.

---

Defining Refractory Septic Shock

While variable consensus thresholds exist in critical care literature, refractory septic shock is generally defined as:

Persistent tissue hypoperfusion and hemodynamic instability requiring high doses of first-line vasopressors (typically norepinephrine $\ge 0.25\text{ to }0.5\text{ mcg/kg/min}$) along with secondary vasoactive agents to maintain a mean arterial pressure (MAP) $\ge 65\text{ mmHg}$, despite adequate fluid loading.

Cellular Pathophysiology of Vasoplegia

Vasodilatory shock in sepsis is driven by four synergistic cellular mechanisms:

1. Inducible Nitric Oxide Synthase (iNOS) Overexpression: Massive inflammatory cytokine release (TNF-$\alpha$, IL-$1\beta$, interferon-$\gamma$) induces vascular endothelial and smooth muscle iNOS, generating pathological levels of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP), forcing profound vascular smooth muscle relaxation.
2. ATP-Sensitive Potassium ($\text{K}_{\text{ATP}}$) Channel Opening: Intracellular ATP depletion and severe lactic acidosis activate vascular $\text{K}_{\text{ATP}}$ channels, hyperpolarizing vascular smooth muscle cell membranes and preventing calcium entry through voltage-gated L-type calcium channels.
3. Adrenergic Receptor Desensitization: High circulating endogenous catecholamine levels promote beta-arrestin binding, G-protein uncoupling, and internalization of vascular $\alpha_1$-adrenergic receptors, resulting in pharmacological tolerance.
4. Neurohypophyseal Vasopressin Depletion: Depletion of pre-formed neurosecretory stores within the posterior pituitary gland leads to an absolute or relative vasopressin deficiency state within hours of shock onset.

---

Vasopressor Escalation Architecture

The Surviving Sepsis Campaign (2021 guideline, updated 2026) outlines a tiered hierarchy for vasoactive initiation and escalation:

                    ┌────────────────────────────────────────┐
                    │ First-Line Vasopressor: Norepinephrine │
                    │ Titrate to 0.25-0.5 mcg/kg/min         │
                    └───────────────────┬────────────────────┘
                                        │
                       MAP < 65 mmHg or Escalating Dose
                                        │
                                        ▼
                    ┌────────────────────────────────────────┐
                    │ Second-Line: Add Fixed-Dose Vasopressin│
                    │ Fixed non-titratable 0.03 units/min    │
                    └───────────────────┬────────────────────┘
                                        │
                     MAP Remains < 65 mmHg Despite Dual Therapy
                                        │
                    ┌───────────────────┴───────────────────┐
                    ▼                                       ▼
        Third-Line: Add Epinephrine             Third-Line: Add Angiotensin II
        (0.05-0.5 mcg/kg/min)                   (1.25-20 ng/kg/min, ATHOS-3)
                    │                                       │
                    └───────────────────┬───────────────────┘
                                        │
          ┌─────────────────────────────┴─────────────────────────────┐
          │ Documented Myocardial Dysfunction or Persistent Hypoperfusion│
          └─────────────────────────────┬─────────────────────────────┘
                                        │
                                        ▼
                    ┌────────────────────────────────────────┐
                    │ Add Inotrope: Dobutamine               │
                    │ Titrate 2.5-20 mcg/kg/min              │
                    └────────────────────────────────────────┘

1. First-Line: Norepinephrine

Norepinephrine is the first-line vasopressor for septic shock: the 2026 SSC recommends it over dopamine, epinephrine, or selepressin (strong) and suggests it over vasopressin or angiotensin II as the first agent (conditional). Norepinephrine acts as a potent $\alpha_1$-adrenoceptor agonist, producing powerful peripheral vasoconstriction that increases systemic vascular resistance (SVR) and mean systemic filling pressure ($P_{\text{msf}}$). It also possesses modest $\beta_1$-adrenergic activity, augmenting stroke volume and supporting heart rate without inducing excessive tachycardia.

Target MAP is $65\text{ mmHg}$ (strong recommendation), and the 2026 SSC suggests 60-65 mmHg for patients aged 65 or older. In SEPSISPAM (NEJM 2014), a higher target (80-85 mmHg) did not reduce mortality and increased atrial fibrillation; in its chronic hypertension subgroup, fewer patients needed renal replacement therapy, a hypothesis-generating finding that does not override the 65 mmHg starting target.

2. Second-Line: Vasopressin (AVP)

For septic shock on escalating doses of norepinephrine, the SSC suggests adding vasopressin (conditional recommendation); the 2021 guideline described the usual practice of adding it when norepinephrine reaches about $0.25\text{ to }0.5\text{ mcg/kg/min}$, typically at a fixed dose of $0.03\text{ units/min}$, rather than escalating norepinephrine indefinitely.

• Mechanism: Vasopressin binds vascular $V_{1a}$ receptors coupled to the $G_q$ pathway, activating phospholipase C and releasing intracellular calcium to restore vascular tone independently of adrenergic receptors. It also directly closes vascular smooth muscle $\text{K}_{\text{ATP}}$ channels and downregulates iNOS expression.
• Dosing Rules: Vasopressin is administered at a fixed, non-titratable infusion rate of $0.03\text{ units/min}$ (or $0.01-0.03\text{ units/min}$). It should NOT be titrated up and down like catecholamines. Infusion rates exceeding $0.03-0.04\text{ units/min}$ cause severe splanchnic vasoconstriction, mesenteric ischemia, coronary spasm, and peripheral digital necrosis.
• Trial Evidence:
  • VASST Trial (NEJM 2008): In 778 septic shock patients, adding low-dose vasopressin spared norepinephrine requirements. While overall 28-day mortality was not significantly different, a pre-defined subgroup analysis of patients with less severe shock (norepinephrine $< 15\text{ mcg/min}$) demonstrated a statistically significant survival benefit with vasopressin ($26.5\%$ vs. $35.7\%$, $p = 0.05$).
  • VANISH Trial (JAMA 2016): Evaluated early vasopressin versus norepinephrine. Vasopressin spared catecholamines and did not improve the primary outcome (kidney failure-free days); fewer survivors in the vasopressin arm received renal replacement therapy ($25.4\%$ vs. $35.3\%$), a secondary finding. A 2018 meta-analysis (McIntyre et al., JAMA) associated vasopressin added to catecholamines with less atrial fibrillation.

3. Third-Line Agents: Epinephrine and Angiotensin II

If shock persists despite norepinephrine and vasopressin:

• Epinephrine: Acts across $\alpha_1$, $\beta_1$, and $\beta_2$ receptors. Epinephrine can be added at $0.05-0.5\text{ mcg/kg/min}$.

  Note

  Epinephrine frequently triggers transient aerobic hyperlactatemia via skeletal muscle $\beta_2$-adrenoceptor stimulation, which stimulates $\text{Na}^+/\text{K}^+$-ATPase and accelerates glycolysis faster than pyruvate dehydrogenase can process pyruvate. This benign lactate rise must not be mistaken for worsening tissue dysoxia when central venous oxygen saturation ($\text{ScvO}_2$) and urine output are improving.

• Angiotensin II (Giapreza): Approved after ATHOS-3 (NEJM 2017), in which adding angiotensin II to high-dose vasopressors raised MAP at 3 hours (primary outcome) and spared catecholamines. 28-day mortality was not significantly different (46% vs. 54%, $p = 0.12$); apparent benefit in patients needing renal replacement therapy or with high renin came from post hoc analyses. The SSC suggests norepinephrine over angiotensin II as the first-line agent, and angiotensin II remains an option for refractory vasodilatory shock.
• 2026 SSC escalation statements: For inadequate MAP despite norepinephrine and vasopressin, suggest adding epinephrine; for septic shock with cardiac dysfunction, suggest either norepinephrine or epinephrine first; suggest against terlipressin and levosimendan, and suggest against beta-blockers as a treatment for septic shock; and there is insufficient evidence to recommend methylene blue or oral midodrine.

---

Inotropic Support & Septic Cardiomyopathy

Septic shock induces acute, reversible myocardial dysfunction—termed septic cardiomyopathy—in 30% to 50% of patients. Pathophysiologically, circulating myocardial depressant factors (TNF-$\alpha$, IL-$1\beta$, endotoxin) cause $\beta$-adrenergic receptor uncoupling, altered sarcoplasmic reticulum calcium handling, and mitochondrial energy starvation. Septic cardiomyopathy is characterized by biventricular dilation, impaired left or right ventricular ejection fraction, elevated cardiac filling pressures, and inadequate cardiac index.

Clinical Management with Dobutamine

The Surviving Sepsis Campaign suggests adding dobutamine to norepinephrine (starting at $2.5\text{ mcg/kg/min}$ and titrating up to $20\text{ mcg/kg/min}$) or using epinephrine alone in patients with:

1. Persistent tissue hypoperfusion (prolonged capillary refill, oliguria, hyperlactatemia, low central venous oxygen saturation [$\text{ScvO}_2 < 70\%$]) despite achieving MAP $\ge 65\text{ mmHg}$ and adequate volume resuscitation.
2. Objective echocardiographic evidence of left or right ventricular myocardial dysfunction.

---

Corticosteroid Therapy: Indications and Evidence

During septic shock, patients frequently develop Critical Illness-Related Corticosteroid Insufficiency (CIRCI), characterized by hypothalamic-pituitary-adrenal axis exhaustion, impaired tissue cortisol delivery, and cellular glucocorticoid receptor downregulation.

Surviving Sepsis Campaign Practice Statements

• Indication: The 2021 guideline suggested (weak recommendation) IV corticosteroids for septic shock with an ongoing norepinephrine (or equivalent) requirement of $\ge 0.25\text{ mcg/kg/min}$ for at least 4 hours. The 2026 guideline suggests IV corticosteroids for adults with septic shock (conditional recommendation) without a specific dose threshold, leaving timing to clinical judgment.
• Regimen: Intravenous Hydrocortisone at a dose of $200\text{ mg/day}$, administered either as $50\text{ mg}$ IV every 6 hours or as a continuous intravenous infusion ($8.3\text{ mg/hr}$).
• Diagnostic Testing: Do NOT perform an ACTH (cosyntropin) stimulation test or draw baseline serum cortisol levels. High-dose cosyntropin tests do not correlate with clinical outcomes and cannot distinguish patients who will benefit from steroids.
• Tapering: Taper corticosteroids once vasopressors are successfully discontinued.

Synthesis of Landmark Corticosteroid Trials

Taken together, ADRENAL and APROCCHSS show consistent faster shock reversal with hydrocortisone, while mortality benefit was seen only in APROCCHSS (with fludrocortisone, in sicker patients). Meta-analyses suggest at most a small mortality benefit, which is why the recommendation is conditional rather than strong.

---

Albumin Administration

During septic shock, extensive shedding of the endothelial glycocalyx and systemic capillary hyperpermeability permit intravascular albumin to extravasate, precipitating hypoalbuminemia and dropping plasma colloid oncotic pressure.

• Surviving Sepsis Campaign Statement: The 2021 guideline suggested albumin for patients who had received large crystalloid volumes. The 2026 guideline suggests crystalloids alone over crystalloids plus albumin (conditional recommendation).
• Trial Evidence:
  • SAFE Trial (NEJM 2004): In a post hoc analysis of 1,218 patients with severe sepsis, resuscitation with 4% albumin was associated with lower adjusted odds of death than saline (odds ratio 0.71, $95\%\text{ CI } 0.52-0.97$); the overall SAFE trial showed no difference.
  • ALBIOS Trial (NEJM 2014): In 1,818 patients with severe sepsis, targeting serum albumin $\ge 30\text{ g/L}$ with 20% albumin did not improve 90-day survival overall; a post hoc analysis of the septic shock subgroup showed lower mortality ($43.6\%$ vs. $49.9\%$), a hypothesis-generating finding.

---

Discredited Therapies: The Vitamin C Controversy

In 2017, a retrospective before-after single-center study by Marik and colleagues claimed that a cocktail of intravenous vitamin C (ascorbic acid), thiamine, and hydrocortisone (the "HAT" protocol) produced near-complete eradication of septic shock mortality. The biological hypothesis proposed that vitamin C scavenges free radicals, preserves endothelial barrier integrity, and acts as a cofactor for endogenous catecholamine and vasopressin synthesis.

Subsequent rigorous, double-blind multicenter randomized controlled trials thoroughly refuted this hypothesis:

• CITRIS-ALI (JAMA 2019): High-dose IV vitamin C failed to improve the primary outcome of modified SOFA score or systemic inflammatory biomarkers.
• VICTAS Trial (JAMA 2021): Evaluated 501 ICU patients with sepsis-induced respiratory or cardiovascular failure. The HAT protocol demonstrated no difference in ventilator- and vasopressor-free days (median 25 vs. 26 days, $p = 0.85$) or 30-day mortality ($22\%$ vs. $24\%$).
• Risks: High-dose parenteral vitamin C causes artifactually false high blood glucose readings on point-of-care glucometers and promotes acute calcium oxalate nephropathy.
• LOVIT (NEJM 2022): In 872 ICU patients with sepsis on vasopressors, IV vitamin C (50 mg/kg every 6 hours) increased the composite of death or persistent organ dysfunction at day 28 (44.5% vs. 38.5%; risk ratio 1.21, 95% CI 1.04-1.40).
• Surviving Sepsis Campaign Statement: Suggests against IV vitamin C (2021 weak recommendation; 2026 conditional recommendation). The 2026 guideline also suggests against IV immunoglobulin, blood purification, polymyxin B hemoperfusion, and vitamin D for sepsis treatment.